Advanced

Initiation of biphasic insulin aspart 30/70 in subjects with type 2 diabetes mellitus in a largely primary care-based setting in Sweden.

Berntorp, Kerstin LU ; Haglund, Mattias; Sjövall Larsen, Sara; Petruckevitch, Ann and Landin-Olsson, Mona LU (2011) In Primary Care Diabetes 5. p.89-94
Abstract
AIMS: Despite a wealth of clinical trial data supporting use of the premixed insulin analogue, biphasic insulin aspart 30 (BIAsp 30) in the treatment of type 2 diabetes mellitus (T2DM), there is limited documentation of its use in primary care-based clinical practice. METHODS: An observational study investigating the safety and efficacy of BIAsp 30 in routine clinical practice was conducted. Patients were followed up 3 and 6 months after initiating insulin treatment. Safety and efficacy measures were documented. RESULTS: During the course of the study, 1154 patients were included (age range 20-95years), of whom 89% completed the 6-month follow-up period. Mean HbA(1c) at baseline was 8.8% (73mmol/mol), and had improved to 7.2% (55mmol/mol)... (More)
AIMS: Despite a wealth of clinical trial data supporting use of the premixed insulin analogue, biphasic insulin aspart 30 (BIAsp 30) in the treatment of type 2 diabetes mellitus (T2DM), there is limited documentation of its use in primary care-based clinical practice. METHODS: An observational study investigating the safety and efficacy of BIAsp 30 in routine clinical practice was conducted. Patients were followed up 3 and 6 months after initiating insulin treatment. Safety and efficacy measures were documented. RESULTS: During the course of the study, 1154 patients were included (age range 20-95years), of whom 89% completed the 6-month follow-up period. Mean HbA(1c) at baseline was 8.8% (73mmol/mol), and had improved to 7.2% (55mmol/mol) after 6 months of treatment. The rate of total hypoglycaemia at completion of the study was 4.1 events per patient year. Major hypoglycaemic events were rare (two in total). CONCLUSIONS: BIAsp 30 was initiated safely and effectively in insulin-naïve patients with T2DM. The safety and efficacy profile observed in clinical trials was confirmed in this largely primary care-based setting in Sweden. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Primary Care Diabetes
volume
5
pages
89 - 94
publisher
Elsevier
external identifiers
  • wos:000304279500004
  • pmid:21440523
  • scopus:79958858255
ISSN
1878-0210
DOI
10.1016/j.pcd.2011.02.003
language
English
LU publication?
yes
id
38dbfdd3-cace-4b15-b000-55bfe380ed14 (old id 1883404)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/21440523?dopt=Abstract
date added to LUP
2011-04-01 21:58:46
date last changed
2017-01-01 07:31:38
@article{38dbfdd3-cace-4b15-b000-55bfe380ed14,
  abstract     = {AIMS: Despite a wealth of clinical trial data supporting use of the premixed insulin analogue, biphasic insulin aspart 30 (BIAsp 30) in the treatment of type 2 diabetes mellitus (T2DM), there is limited documentation of its use in primary care-based clinical practice. METHODS: An observational study investigating the safety and efficacy of BIAsp 30 in routine clinical practice was conducted. Patients were followed up 3 and 6 months after initiating insulin treatment. Safety and efficacy measures were documented. RESULTS: During the course of the study, 1154 patients were included (age range 20-95years), of whom 89% completed the 6-month follow-up period. Mean HbA(1c) at baseline was 8.8% (73mmol/mol), and had improved to 7.2% (55mmol/mol) after 6 months of treatment. The rate of total hypoglycaemia at completion of the study was 4.1 events per patient year. Major hypoglycaemic events were rare (two in total). CONCLUSIONS: BIAsp 30 was initiated safely and effectively in insulin-naïve patients with T2DM. The safety and efficacy profile observed in clinical trials was confirmed in this largely primary care-based setting in Sweden.},
  author       = {Berntorp, Kerstin and Haglund, Mattias and Sjövall Larsen, Sara and Petruckevitch, Ann and Landin-Olsson, Mona},
  issn         = {1878-0210},
  language     = {eng},
  pages        = {89--94},
  publisher    = {Elsevier},
  series       = {Primary Care Diabetes},
  title        = {Initiation of biphasic insulin aspart 30/70 in subjects with type 2 diabetes mellitus in a largely primary care-based setting in Sweden.},
  url          = {http://dx.doi.org/10.1016/j.pcd.2011.02.003},
  volume       = {5},
  year         = {2011},
}